Trump Strikes Deal with Regeneron for Discounted Drug Prices

In a significant move on Thursday, President Donald Trump revealed a groundbreaking agreement with drugmaker Regeneron aimed at lowering pharmaceutical costs for Medicaid recipients. This aligns with the White House's broader initiative to address high drug prices ahead of the midterm elections, reflecting Trump's ongoing efforts to achieve economic relief, particularly in healthcare.

Under the deal, Regeneron will reduce prices for its existing and future drugs, including the cholesterol medication Praluent, which will be available for USD 225 on the discounted platform TrumpRx. This agreement, part of several 'most-favored-nation' deals, aims to bring U.S. drug prices in line with those of other developed countries.

The President, with a history of lauding Regeneron, emphasized the potential electoral impact of such deals and mentioned Regeneron's commitment to substantial research and development investments in the U.S. Additionally, Regeneron's new gene therapy was approved by the FDA, underscoring the ongoing debate over drug-pricing strategies during Trump's administration.